Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by Bristol-Myers Squibb
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01766817
First received: January 10, 2013
Last updated: June 17, 2015
Last verified: June 2015

January 10, 2013
June 17, 2015
January 2013
April 2016   (final data collection date for primary outcome measure)
Rate of change in forced vital capacity (FVC) [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
Compare BMS-986020 600 mg once daily or BMS-986020 600 mg twice daily, vs. placebo.
Same as current
Complete list of historical versions of study NCT01766817 on ClinicalTrials.gov Archive Site
  • Safety [ Time Frame: 26 weeks ] [ Designated as safety issue: Yes ]
    Safety and tolerability will be measured based on AEs, vital signs, and standard clinical laboratory tests, including routine hematology, blood chemistry, and urinalysis.
  • Quantitative Lung Fibrosis (QLF) score on HRCT [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
    Exploratory endpoint elevated to key secondary endpoint in Protocol Amendment 07 dated 06Feb2015; QLF shown in recent studies to be a sensitive clinical biomarker of progression of fibrosis and concordance observed between FVC change and QLF change.
  • Change in 6 Minute Walk Test and Dyspnea [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
    To assess the effect of treatment with BMS-986020 on change in 6 minute walk distance and change in dyspnea in patients with IPF.
  • Pharmacokinetic (PK) Endpoint [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
    Pharmacokinetic (PK) is a secondary endpoint and will be an estimate of the systemic exposure of BMS-986020 in subjects with IPF following single- and multiple-dose administration.
Safety [ Time Frame: 26 weeks ] [ Designated as safety issue: Yes ]
Safety will be measured based on AEs, vital signs, and clinical laboratory tests.
Not Provided
Not Provided
 
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF).

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Idiopathic Pulmonary Fibrosis
  • Drug: BMS-986020
  • Drug: Placebo matching with BMS-986020
  • Experimental: Arm 1: BMS 986020, 600 mg. once daily
    BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks
    Intervention: Drug: BMS-986020
  • Experimental: Arm 2: BMS-986020, 600 mg twice daily
    BMS-986020, 600 mg tablets, by mouth, twice daily, 26 weeks
    Intervention: Drug: BMS-986020
  • Placebo Comparator: Arm 3: Placebo matching with BMS-986020
    Placebo, 0 mg tablets, by mouth, twice daily, 26 weeks
    Intervention: Drug: Placebo matching with BMS-986020
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
135
May 2016
April 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Are between the ages of 40 and 90 years, inclusive, at randomization.
  • Have clinical symptoms consistent with IPF.
  • Have first received a diagnosis of IPF less than 6 years before randomization. The date of diagnosis is defined as the date of the first available imaging or surgical lung biopsy consistent with IPF/UIP.
  • Have a diagnosis of usual interstitial pulmonary fibrosis (UIP) or IPF by HRCT or surgical lung biopsy (SLB).
  • Extent of fibrotic changes (honeycombing, reticular changes) greater than the extent of emphysema on HRCT scan.
  • Have no features supporting an alternative diagnosis on transbronchial biopsy, BAL, or SLB, if performed.
  • Have percent predicted post-bronchodilator FVC between 45% and 90%, inclusive, at screening.
  • Have a change in post-bronchodilator FVC (measured in liters) between screening and day 1 that is less than a 10% relative difference, calculated as: the absolute value of 100% * (screening FVC (L) - day 1 FVC (L)) / screening FVC (L).
  • Have carbon monoxide diffusing capacity (DLCO) between 30% and 80% (adjusted for hemoglobin and altitude), inclusive, at screening.
  • Have no evidence of improvement in measures of IPF disease severity over the preceding year, in the investigator's opinion.
  • Be able to walk 150 meters or more at screening.
  • Demonstrate an exertional decrease in oxygen saturation of 2 percentage points or greater at screening (may be performed with supplemental oxygen titrating to keep oxygen saturation levels >88%).
  • Are able to understand and sign a written informed consent form.
  • Are able to understand the importance of adherence to study treatment and the study protocol and are willing to comply with all study requirements, including the concomitant medication restrictions, throughout the study.
  • Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must use acceptable method(s) of contraception. The individual methods of contraception and duration should be determined in consultation with the investigator. WOCBP must follow instructions for birth control when the half-life of the investigational drug is less than 24 hours, contraception should be continued for a period of 30 days after the last dose of investigational product.

    1. Women must have a negative urine pregnancy test within 24 hours prior to the start of investigational product.
    2. Women must not be breastfeeding.
    3. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men that are sexually active with WOCBP must follow instructions for birth control when the half-life of the investigational drug is less than 24 hours, contraception should be continued for a period of 90 days after the last dose of investigational product.
    4. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic men do not require contraception.

Exclusion Criteria:

Target Disease Exclusions

  1. Has significant clinical worsening of IPF between screening and day 1 (during the screening process), in the opinion of the investigator.
  2. Has forced expiratory volume in 1 second (FEV1)/FVC ratio less than 0.8 after administration of bronchodilator at screening.
  3. Has bronchodilator response, defined by an absolute increase of 12% or greater and an increase of 200 mL in FEV1 or FVC or both after bronchodilator use compared with the values before bronchodilator use at screening.

Medical History and Concurrent Diseases

  1. Has a history of clinically significant environmental exposure known to cause pulmonary fibrosis, including, but not limited to, drugs (such as amiodarone), asbestos, beryllium, radiation, and domestic birds.
  2. Has a known explanation for interstitial lung disease, including, but not limited to, radiation, drug toxicity, sarcoidosis, hypersensitivity, pneumonitis, bronchiolitis, obliterans, organizing pneumonia, human immunodeficiency virus (HIV), viral hepatitis, and cancer.
  3. Has a clinical diagnosis of any connective tissue disease, including, but not limited to, scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis, and undifferentiated connective tissue disease.
  4. Currently has clinically significant asthma or chronic obstructive pulmonary disease.
  5. Has clinical evidence of active infection, including, but not limited to, bronchitis, pneumonia, sinusitis, urinary tract infection, and cellulitis.
  6. Has any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 2 years. This does not include minor surgical procedures for localized cancer (e.g., basal cell carcinoma).
  7. Has any condition other than IPF that, in the opinion of the investigator, is likely to result in the death of the subject within the next 2 years.
  8. Has a history of end-stage liver disease.
  9. Has a history of end-stage renal disease requiring dialysis.
  10. Has a history of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months, including, but not limited to, the following: i. Unstable angina pectoris or myocardial infarction ii. Congestive heart failure requiring hospitalization iii. Uncontrolled clinically significant arrhythmias
  11. Has any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of BMS-986020.
  12. Has a history of alcohol or substance abuse in the past 2 years.
  13. Has a family or personal history of long QT syndrome and/or Torsades de Pointes (polymorphic ventricular tachycardia).
  14. Has used any of the excluded medications per Appendix 1 of the Protocol, which includes, but is not limited to:

    • current treatment with pirfenidone or nintedanib
    • use of over-the-counter medications and herbal preparations, within 4 weeks before study drug administration except those medications cleared by the BMS medical monitor
    • For subjects taking statins, there are restrictions on the maximum allowable doses for statins listed below. If subjects are currently taking statins and their doses are higher than those mentioned below, please reduce the dose to the maximum allowable dose.

Additionally, if subjects are on statins and ready to start dosing, these subjects should limit statin doses by maximal allowable dose or lower for at least 5 days prior to the first BMS-986020 dosing. Shorter durations may be considered in select cases after discussion with the medical monitor.

Maximum allowable dose for statins:

  • Simvastatin 20 mg QD
  • Pitavastatin 2 mg QD
  • Atorvastatin 40 mg QD
  • Pravastatin 40 mg QD
  • Rosuvastatin 20 mg QD
  • Lovastatin 40 mg QD
  • Fluvastatin 40 mg QD
  • Prednisone is allowed up to a maximum of 15 mg po daily
  • Pirfenidone or nintedanib dosing for a maximum of 3 months in the prior 12 months is permitted with a 4 week washout period prior to dosing with BMS-986020.

Physical and Laboratory Test Findings

  1. Has any of the following liver-function test criteria above the specified limits: total bilirubin >1.5 x ULN, excluding subjects with Gilbert's syndrome; aspartate or alanine aminotransferase (AST/SGOT or ALT/SGPT) greater than 3 x ULN; alkaline phosphatase greater than 2.5 x ULN.
  2. Has creatinine clearance less than 30 mL/minute, calculated using the Cockcroft-Gault formula.
  3. Has ECG result with a QT interval by Fridericia's correction (QTcF) of 500 msec or greater or an uncorrected QT of 500 msec or greater at screening. Note: For subjects with a machine read QT interval of >500 msec, if their heart rate is > 100 bpm, the machine read QT interval (either corrected or not) may not be accurate. If the investigator is uncertain about the QT abnormality, it is recommended that ECGs be over-read by a cardiologist. The manually read QT interval by a cardiologist should be used for assessment of eligibility whenever possible.

Allergies and Adverse Drug Reaction Has had prior use of BMS-986020 or has known hypersensitivity to any of the components of study treatment.

Other Exclusion Criteria

  1. Is not a suitable candidate for enrollment or is unlikely to comply with the requirements of this study, in the opinion of the investigator.
  2. Has smoked cigarettes within 4 weeks or screening or is unwilling to avoid tobacco products throughout the study.
  3. Is expected to receive a lung transplant within 1 year from randomization or, for subjects at sites in the United States, is on a lung-transplant waiting list at screening.
  4. Prisoners or subjects who are involuntarily incarcerated.
  5. Subjects who are compulsorily detained for treatment either of a psychiatric or physical (e.g., infectious disease) illness.
  6. Inability to comply with restrictions and prohibited activities/treatments as listed in Section 3.3 of the Protocol.
Both
40 Years to 90 Years
No
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT# and Site #.
United States,   Australia,   Chile,   Colombia,   Mexico,   Peru
 
NCT01766817
IM136-003
Yes
Bristol-Myers Squibb
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP